Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report

• Published in: Journal of allergy and clinical immunology Vol. 117; no. 6; pp. 1292 - 1302
• Main Authors: Klion, Amy D., Bochner, Bruce S., Gleich, Gerald J., Nutman, Thomas B., Rothenberg, Marc E., Simon, Hans-Uwe, Wechsler, Michael E., Weller, Peter F., the Hypereosinophilic Syndromes Working Group
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Mosby, Inc 01.06.2006; Elsevier; Elsevier Limited
• Subjects: Airway management; Biological and medical sciences; Biomarkers; Churg-Strauss syndrome; Disease; Disease Progression; Drug dosages; Drug therapy; Eosinophil; eosinophil-associated gastrointestinal disease; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; Hypereosinophilic Syndrome - diet therapy; Hypereosinophilic Syndrome - drug therapy; Hypereosinophilic Syndrome - immunology; Hypereosinophilic Syndrome - therapy; hypereosinophilic syndromes; Immunopathology; Medical sciences; treatment; hypereosinophilic syndromes; EE; treatment; PDGFRA; CSS; Eosinophil; IHES; Churg-Strauss syndrome; L-HES; FIP1L1; ANCA; eosinophil-associated gastrointestinal disease; HES; EGID; Granulomatous vasculitis; Immunopathology; Churg Strauss syndrome; Granulocyte; Cardiovascular disease; Hemopathy; Gastrointestinal; Vascular disease; Churg- Strauss syndrome; Immunology; Treatment; Workshop; Hypereosinophilic syndrome
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/j.jaci.2006.02.042

Hypereosinophilic syndromes are a heterogeneous group of uncommon disorders characterized by the presence of marked peripheral blood eosinophilia, tissue eosinophilia, or both, resulting in a wide variety of clinical manifestations. Although corticosteroids are the first-line therapy for many of these disorders, approaches to the treatment of patients who do not tolerate or are unresponsive to corticosteroids are poorly standardized. A multidisciplinary group of 37 clinicians and scientists participated in a workshop held in May 2005 in Bern, Switzerland to discuss current and future approaches to therapy for 3 eosinophil-mediated disorders: hypereosinophilic syndrome, Churg-Strauss syndrome, and eosinophil-associated gastrointestinal disease. The goal of the workshop was to summarize available data regarding treatment of these disorders to identify the most promising therapies and approaches for further study. There was consensus among all of the participants that the identification of markers of disease progression to assess treatment responses is a research priority for all 3 disorders. Furthermore, the need for newer therapeutic strategies and novel drugs, as well as multicenter trials to assess all treatment modalities, was emphasized.